DNA Replication: A new role for a tumor-suppressing protein
In addition to its role in preventing tumors, the protein p53 appears to participate in a DNA repair process known as the replication-stress response.
- Memorial Sloan Kettering Cancer Center, United States
Over half of all cancers involve mutations in a protein called p53. Dubbed the ‘guardian of the genome’, p53 can kill mutated cells or prevent such cells from multiplying, which stops tumors from growing. However, if p53 itself becomes faulty, cells with damaged DNA can accumulate and potentially lead to cancer. Besides its ability to eliminate ‘rogue’ cells, p53 may also be able to help prevent permanent mutations from appearing in the first place (Williams and Schumacher, 2016). For example, it can remove damaged bases and nucleotides from DNA, or promote mechanisms that repair harmful DNA breaks (Offer et al., 2001; Romanova et al., 2004; Wang et al., 1995).
There has been mounting evidence that p53 may also be involved in DNA replication, the error-prone process by which a cell makes a copy of its DNA before it divides. When DNA replicates, the double-helix unzips and forms Y- shaped structures called replication forks. If replication is disrupted, the forks may slow down and stall. This activates the ‘replication-stress response’, a mechanism that can recruit proteins to repair damaged DNA, restart the stalled fork, and ensure that replication carries on without mutations. Now, in eLife, Katharina Schlacher and colleagues at the UT MD Anderson Cancer Center and the Wistar Institute – including Sunetra Roy as first author – report that p53 may have a previously unknown role as a regulator of the replication-stress response (Roy et al., 2018).
In particular, they used a technique called DNA fiber assays to measure the number of stalled and restarted replication forks. They found that when p53 is defective, stalled replication forks could not restart properly. The role of p53 in restarting replication is different from its role in eliminating damaged cells, with certain p53 mutants being able to perform one role but not the other. This finding was similar to what has been described about the regulation of homologous recombination by p53 (Romanova et al., 2004; Willers et al., 2000), and future work will determine whether these two sets of observations are connected.
Roy et al. then examined whether p53 regulates the restart of stalled forks indirectly (via activation of gene expression) or directly (through protein-protein interactions at the replication fork). When a fork stalls, multiple molecules are recruited at the site, where they trigger the replication-stress response: p53 is known to bind with several of these (Byun et al., 2005; Romanova et al., 2004). Using normal and cancer cells from humans and mice, Roy et al. discovered that p53 is physically present at both active and stalled replication forks. When p53 worked correctly, it bound to the replication fork and ensured that replication resumed efficiently after it had passed any faulty regions of DNA. However, mutant p53 could no longer bind the replication fork, and stalled forks could not resume their activity properly.
Next, Roy et al. investigated how p53’s presence promoted stalled forks to restart. Their results showed that p53 recruited MLL3, a protein that can modify how chromatin – the structure into which the DNA is packed – is arranged (Zhu et al., 2015). These changes to the chromatin could attract another protein called MRE11 on the fork. This enzyme prevents DNA from breaking following replication stress (Berti and Vindigni, 2016; Costanzo et al., 2001; Ray Chaudhuri et al., 2016).
Finally, Roy et al. showed that when p53 was absent or mutated, two alternative DNA repair systems took over. These involved proteins called RAD52 and Polθ, which were increasingly recruited to the stalled replication forks. However, these two proteins are known to cause mutations, which could lead to an accumulation of genomic damage and perhaps cancer. Indeed, in breast tumors that lack a working version of p53, the DNA is damaged in ways that could have been provoked by RAD52 and Polθ.
Taken together, these results suggest that p53 is present at replication forks and plays a crucial role in the replication-stress response (Figure 1). When a fork stalls, p53 recruits proteins that fix the errors and efficiently restart replication. If p53 is absent or mutated, the stalled fork enlists other repair proteins that can make it restart, but which are prone to cause mutations. Are these mistakes enough to cause cancer? And could suppressing these back-up proteins help treat cancers caused by mutations in p53? This remains to be explored.
Figure 1
Schematic showing the role of p53 at the replication fork.
When the DNA (black) replicates, the double helix opens to form a Y-shape called the replication fork. One new strand (the leading strand; green arrow) runs towards the replication fork, while the other (the lagging strand; green arrows at top) runs away from it. When a DNA lesion is encountered (in red), the replication fork may stall. Sometimes, however, the DNA continues to unwind ahead of the fork, leading to the formation of stretches of single-stranded DNA. This triggers a ‘replication-stress response’, which includes enlisting the protein p53 to the replication fork. In turn, p53 recruits MLL3 and then MRE11, which can modify the structure of nearby chromatin and prevent DNA breakage. This allows replication to restart and ensures that genetic information is preserved (genomic stability). Without p53, two proteins called RAD52 and Polθ are recruited to the stalled fork instead. Although these two proteins help to repair DNA, they can also lead to an accumulation of mutations (genomic instability).
References
-
Replication stress: getting back on trackNature Structural & Molecular Biology 23:103–109.https://doi.org/10.1038/nsmb.3163
-
p53 modulation of TFIIH-associated nucleotide excision repair activityNature Genetics 10:188–195.https://doi.org/10.1038/ng0695-188
-
p53 in the DNA-Damage-Repair processCold Spring Harbor Perspectives in Medicine 6:a026070.https://doi.org/10.1101/cshperspect.a026070
Article and author information
Author details
Publication history
Copyright
© 2018, Setton et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,182
- views
-
- 212
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
DNA Replication: A new role for a tumor-suppressing protein
eLife 7:e35111.
https://doi.org/10.7554/eLife.35111
Further reading
-
- Chromosomes and Gene Expression
- Immunology and Inflammation
Genome-wide association studies (GWAS) have identified hundreds of genetic signals associated with autoimmune disease. The majority of these signals are located in non-coding regions and likely impact cis-regulatory elements (cRE). Because cRE function is dynamic across cell types and states, profiling the epigenetic status of cRE across physiological processes is necessary to characterize the molecular mechanisms by which autoimmune variants contribute to disease risk. We localized risk variants from 15 autoimmune GWAS to cRE active during TCR-CD28 co-stimulation of naïve human CD4+ T cells. To characterize how dynamic changes in gene expression correlate with cRE activity, we measured transcript levels, chromatin accessibility, and promoter–cRE contacts across three phases of naive CD4+ T cell activation using RNA-seq, ATAC-seq, and HiC. We identified ~1200 protein-coding genes physically connected to accessible disease-associated variants at 423 GWAS signals, at least one-third of which are dynamically regulated by activation. From these maps, we functionally validated a novel stretch of evolutionarily conserved intergenic enhancers whose activity is required for activation-induced IL2 gene expression in human and mouse, and is influenced by autoimmune-associated genetic variation. The set of genes implicated by this approach are enriched for genes controlling CD4+ T cell function and genes involved in human inborn errors of immunity, and we pharmacologically validated eight implicated genes as novel regulators of T cell activation. These studies directly show how autoimmune variants and the genes they regulate influence processes involved in CD4+ T cell proliferation and activation.
-
- Chromosomes and Gene Expression
- Developmental Biology
Differentiation of female germline stem cells into a mature oocyte includes the expression of RNAs and proteins that drive early embryonic development in Drosophila. We have little insight into what activates the expression of these maternal factors. One candidate is the zinc-finger protein OVO. OVO is required for female germline viability and has been shown to positively regulate its own expression, as well as a downstream target, ovarian tumor, by binding to the transcriptional start site (TSS). To find additional OVO targets in the female germline and further elucidate OVO’s role in oocyte development, we performed ChIP-seq to determine genome-wide OVO occupancy, as well as RNA-seq comparing hypomorphic and wild type rescue ovo alleles. OVO preferentially binds in close proximity to target TSSs genome-wide, is associated with open chromatin, transcriptionally active histone marks, and OVO-dependent expression. Motif enrichment analysis on OVO ChIP peaks identified a 5’-TAACNGT-3’ OVO DNA binding motif spatially enriched near TSSs. However, the OVO DNA binding motif does not exhibit precise motif spacing relative to the TSS characteristic of RNA polymerase II complex binding core promoter elements. Integrated genomics analysis showed that 525 genes that are bound and increase in expression downstream of OVO are known to be essential maternally expressed genes. These include genes involved in anterior/posterior/germ plasm specification (bcd, exu, swa, osk, nos, aub, pgc, gcl), egg activation (png, plu, gnu, wisp, C(3)g, mtrm), translational regulation (cup, orb, bru1, me31B), and vitelline membrane formation (fs(1)N, fs(1)M3, clos). This suggests that OVO is a master transcriptional regulator of oocyte development and is responsible for the expression of structural components of the egg as well as maternally provided RNAs that are required for early embryonic development.
